Therapeutic fusion proteins

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10704038
APP PUB NO 20190062721A1
SERIAL NO

16105203

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to the construction of a new class of Targeted Secretion Inhibitors (TSIs), which comprise a non-cytotoxic protease, translocation peptide and a targeting moiety peptide, wherein the targeting moiety peptide has a free N-terminal domain and a free C-terminal domain; to a single-chain fusion protein precursor thereof, and to a method of activating said single-chain fusion protein precursor.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
IPSEN BIOINNOVATION LIMTIED102 PARK DRIVE MILTON PARK ABINGDON OX14 4RY

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Chaddock, John Abingdon, GB 48 821
Harper, Elaine Abingdon, GB 5 14

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 7, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 7, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00